drugset
drugset / Trial / NCT05501340

PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites

NCT05501340 ↗

Phase 1/2 Unknown 40 enrolled Second Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients with peritoneal metastasis of advanced malignant tumors and malignant ascites. It is planned to determine the safety and efficacy of intraperitoneal infusion of PD-1 inhibitor combination with PRaG therapy.

Timeline

Start
2022-09-01
Primary completion
2022-12-31
Completion
2024-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Molgramostim Protein / enzyme biologic 200 ug Subcutaneous
Subject Serplulimab Monoclonal antibody 3 mg/kg Other
Subject Serplulimab Monoclonal antibody 100 mg Other

Indications

peritoneal neoplasm